LMR Partners’s BridgeBio Pharma BBIO Stock Holding History

LMR Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36,400	Closed	-$2.78M	–	1467
2025 Q4	$2.78M	Hold	36,400	–	–	0.01%	728
2025 Q3	$1.89M	Hold	36,400	–	–	0.01%	752
2025 Q2	$1.57M	Hold	36,400	–	–	0.01%	701
2025 Q1	$1.26M	Sell	36,400 -107,300	-75%	-$3.62M	0.01%	740
2024 Q4	$3.94M	Buy	143,700 +43,700	+44%	+$1.13M	0.03%	446
2024 Q3	$2.55M	Buy	100,000 +80,000	+400%	+$2.1M	0.02%	538
2024 Q2	$507K	Buy	+20,000	New	+$547K	﹤0.01%	767
2024 Q1	–	Sell	-25,000	Closed	-$1.01M	–	1159
2023 Q4	$1.01M	Buy	+25,000	New	+$751K	0.01%	580
2023 Q3	–	Sell	-5,400	Closed	-$92.9K	–	940
2023 Q2	$92.9K	Buy	+5,400	New	+$81.3K	﹤0.01%	629

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's BBIO Position: Q4 2025 in Review

LMR Partners sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 5,000 shares — an estimated $328K sold.

LMR Partners first reported a position in BBIO in Q2 2023 and held it in 6 quarters. The position peaked at $2.67M in Q3 2024. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

LMR Partners reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
LMR Partners sold 5,000 BridgeBio Pharma shares in Q4 2025, an estimated $328K.
LMR Partners first reported a position in BridgeBio Pharma in Q2 2023 and held it in 6 quarters.
LMR Partners's BridgeBio Pharma position peaked at $2.67M in Q3 2024.
432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on LMR Partners's 13F filing for Q4 2025, filed 17 Feb 2026.